Expands treatment capabilities, reduces treatment time, and improves
overall experience with UltraShape and VelaShape systems
YOKNEAM, Israel, May 16, 2013 /CNW/ - Syneron Medical Ltd.
(NASDAQ: ELOS), the leading global aesthetic device company, announced
today the introduction of new enhancements to its innovative body
shaping products, including the UltraShape® V3 system, which is
currently available in Canada, Europe, Latin America, and Asia, and the
VelaShape® II system, which has a market leading installed base and is
available globally. The enhancements, which are based on physician and
patient feedback, are designed to significantly increase the return on
investment for physicians, reduce number of treatments, and improve
patient experience and comfort.
(Logo: http://photos.prnewswire.com/prnh/20120528/535447 )
The UltraShape V3 system is a clinically proven non-invasive solution
for fat reduction and body contouring using "non-thermal" focused
ultrasound technology. This unique fat selective technology gives
physicians a comprehensive body sculpting solution that enables
targeted, non-invasive fat destruction. The enhancements to the
UltraShape V3 system include:
• U-Sculpt transducer (delivers focused ultrasound treatment) - the new U-Sculpt transducer is smaller and 50% lighter than the
current full-size transducer. The U-Sculpt is ergonomically designed,
includes more treatment pulses, and is easily interchangeable with the
full-size transducer during treatment sessions.
• Re-usable strap sets (used to gather skin and fat tissue at the
treatment area) -designed to quickly and effectively lift and gather tissue in the
target area to increase treatment efficiency.
• Ultrasonic treatment gel (allows focused ultrasound energy to be
delivered through the skin) - designed to reduce treatment preparation time and provide patients
with a cleaner, more streamlined procedure compared to the previous
The UltraShape V3 enhancements will be available to current UltraShape
customers beginning in May 2013 and will also be included in all new
UltraShape V3 system purchases.
"As a long time and satisfied UltraShape user, I find the new U-Sculpt
transducer a great enhancement," commented Mr. Christopher Inglefield
BSc, MBBS, FRCS. "U-Sculpt is light and easy to move around and enables
me to treat small areas which were not reachable with the larger
transducer. In addition, the new treatment set up using the gel and
straps, minimizes the preparation time significantly, a fact that is
well appreciated by both my patients and my staff."
The VelaShape system, featuring Syneron's proprietary elos technology,
was the first FDA cleared device for noninvasive Circumferential
Reduction. VelaShape has an installed base of more than 7,000 systems
worldwide, has been clinically proven in over a dozen studies, and
there have been more than 5 million independent VelaShape treatments
globally. The enhancements to the VelaShape II system include:
• New treatment protocol and disposable cover for circumferential
reduction - offers patients the same efficacy with 50% fewer treatment sessions.
The new VelaShape II disposable treatment cover will be available in May
2013 and will be featured in product demonstrations at the Company's
booth #709 at THE Aesthetics Show multidisciplinary medical education
meeting, May 17-19, 2013 in Las Vegas, NV.
Dr. Shimon Eckhouse, Chief Executive Officer of Syneron, said,
"VelaShape is the best-selling product in the history of Syneron. We
believe we have made the system even more attractive to our customers
and their patients by enabling faster, more effective circumferential
reduction treatment capabilities. Combined with UltraShape, we have the
most innovative and broadly used body shaping product portfolio on the
market and are well positioned to lead the global market of
non-invasive body contouring."
To learn more about the UltraShape and VelaShape Systems, visit http://www.Syneron-Candela.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic
device company with a comprehensive product portfolio and a global
distribution footprint. The Company's technology enables physicians to
provide advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, rejuvenation of the skin's appearance through the treatment
of superficial benign vascular and pigmented lesions, and the treatment
of acne, leg veins and cellulite. The Company sells its products under
two distinct brands, Syneron and Candela. Founded in 2000, the
corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd.
are located in Israel. Syneron also has R&D and manufacturing
operations in the US. The Company markets, services and supports its
products in 90 countries. It has offices in North America, France,
Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong
Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations,
beliefs, goals, plans or prospects constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Further, any statements that are not statements of
historical fact (including statements containing "believes,"
"anticipates," "plans," "expects," "may," "will," "would," "intends,"
"estimates" and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements, such as the
company's ability to effectively market the new enhancements, as well
as the risks set forth in Syneron Medical Ltd.'s most recent Annual
Report on Form 20-F, and the other factors described in the filings
that Syneron Medical Ltd. makes with the SEC from time to time. If one
or more of these factors materialize, or if any underlying assumptions
prove incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results, performance
or achievements expressed or implied by these forward-looking
In addition, the statements in this document reflect the expectations
and beliefs of Syneron Medical Ltd. as of the date of this document.
Syneron Medical Ltd. anticipates that subsequent events and
developments will cause its expectations and beliefs to change.
However, while Syneron Medical Ltd. may elect to update these
forward-looking statements publicly in the future, it specifically
disclaims any obligation to do so. The forward-looking statements of
Syneron Medical Ltd. do not reflect the potential impact of any future
dispositions or strategic transactions that may be undertaken. These
forward-looking statements should not be relied upon as representing
Syneron Medical Ltd.'s views as of any date after the date of this
SOURCE: Syneron Medical Ltd.
For further information:
Syneron Public Relations
Hugo Goldman, Chief Financial Officer
Zack Kubow, The Ruth Group